SCHEMBL939729

SCHEMBL939729

NC[C@@H](O)[C@@H]1C=CCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL939730 1.00
SCHEMBL1482554 1.00
SCHEMBL1482557 1.00
SCHEMBL4049831 1.00
SCHEMBL4366326 1.00
SCHEMBL15276137 0.82
SCHEMBL15276139 0.82
SCHEMBL12391901 0.80
SCHEMBL12216536 0.80
SCHEMBL16214673 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160361295-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-12-15 US disclosed
US-20160361295-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-12-15 US disclosed
US-20160015685-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-01-21 US disclosed
US-20160015685-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2016-01-21 US disclosed
US-20150209349-A1 Piperazine Compounds AMURA THERAPEUTICS LTD (GB) 2015-07-30 US disclosed
US-20150209349-A1 Piperazine Compounds AMURA THERAPEUTICS LTD (GB) 2015-07-30 US disclosed
EP-2240491-B1 TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES AMURA THERAPEUTICS LTD (GB) 2015-07-15 EP disclosed
US-20150164912-A1 FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS AMURA THERAPEUTICS LTD (GB) 2015-06-18 US disclosed
US-9045492-B2 Piperazine compounds AMURA THERAPEUTICS LIMITED (GB) 2015-06-02 US disclosed
US-9045492-B2 Piperazine compounds AMURA THERAPEUTICS LIMITED (GB) 2015-06-02 US disclosed
WO-2009112826-A1 FURO [3, 2-B] PYRR0L-3-0NES AS CATHEPSIN S INHIBITORS AMURA THERAPEUTICS LIMITED (GB) 2009-09-17 WO disclosed
CN-101511841-A Tetrahydrofuro [3, 2-B ] pyrrol-3-ones as cathepsin K inhibitors ARMURA THERAPEUTICS LTD (GB) 2009-08-19 CN disclosed
US-20090203714-A1 Furo[3,2-B]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors AMURA THERAPEUTICS LIMITED (GB) 2009-08-13 US disclosed
CN-101506185-A Tetrahydrofuro [3, 2-B] pyrrol-3-one intermediates ARMURA THERAPEUTICS LTD (GB) 2009-08-12 CN disclosed
US-20090197817-A1 Tetrahdrofuro[3,2-B] pyrrol-3- one as cathepsin k inhibitors AMURA THERAPEUTICS LIMITED (GB) 2009-08-06 US disclosed
US-20090192170-A1 Furo[3,2-B] pyrrol -3-one derivatives and their use as cysteinyl porteinase inhibitors AMURA THERAPEUTICS LIMITED (GB) 2009-07-30 US disclosed
US-20090192322-A1 Tetrahydrofuro[3,2-b] pyrrol-3-one intermediates AMURA THERAPEUTICS LIMITED (GB) 2009-07-30 US disclosed
US-20090186906-A1 N-((S)-4,4-dimethyl-1-oxo-1-((3aS,6aR)-3-oxo-dihydro-2H-furo[3,2-b]pyrrol-4(5H6H, 6aH)-yl)pentan-2-yl)-4-(4-methylpiperazin-1-yl)benzamide; treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, bone cancer AMURA THERAPEUTICS LIMITED (GB) 2009-07-23 US disclosed
US-20090186831-A1 Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases AMURA THERAPEUTICS LIMITED (GB) 2009-07-23 US disclosed
US-20090186831-A1 Tetrahydrofuro(3,2-B) pyrrol-3-one derivatives as inhibitors of cysteine proteinases AMURA THERAPEUTICS LIMITED (GB) 2009-07-23 US disclosed